Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Energean remains committed to sale of Egypt, Italy and Croatia assets

(Sharecast News) - Energean remains committed to the sale of its portfolio in Egypt, Italy and Croatia to an outfit controlled by Carlyle International Energy Partners. Mathios Rigas, chief executive of Energean, said: "Although the necessary regulatory approvals have not yet been obtained by Carlyle, we remain committed to closing the Transaction.

"These are high-quality, diversified assets with significant growth potential and, if the Transaction does not close, we will assess all strategic options, focussing, as always, on the best interests of our shareholders keeping in mind the need for diversification, scale, dividend accretion and growth."

The company's statement came ahead of the 20 March longstop date for transaction close.

Carlyle had yet to obtain regulatory approvals in Italy and Egypt, as well as antitrust approvals in Italy, Egypt and Common Market for Eastern and Southern Africa.

So absent an extension being agreed, the transaction could be terminated in accordance with the provisions of the SPA, Energean explained.

But Energean was committed to the sale under the terms of the SPA, the company said.

It was also still committed to maximising shareholder returns via its dividends - regardless of the sale going through or not.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.